Our immediate objective is to identify, characterize, and establish distinct MET SVs, such as GFs and copy gain, as potent precision medicine targets in DMGs.
Previous PostInvestigating the tumorigenesis mechanisms and vulnerabilities of pediatric high-grade gliomas with H3G34R/V
Next PostElucidating Heterogeneity of Resistance Across Molecular Subgroups of Pediatric Ependymomas to Inform Future Therapeutics
